

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-158 (Cancelled).

159. (New) A method of detection and/or quantification of a target nucleic acid sequence and/or a nucleic acid amplification reaction using a nucleic acid amplification comprising the step of:

having a Molecular Energy Transfer (MET)/Fluorescent Resonance Energy Transfer (FRET) between a donor MET/FRET moiety and an acceptor MET/FRET moiety separately on at least two separate oligonucleotides,

wherein the said moieties on two oligonucleotides are provided in the oligonucleotides on a base at least 2 bases away from its 3' end is adapted to inhibit signal from primer dimer, and eliminate non-specific signal generation when the (MET/FRET moiety) labelled oligonucleotides are subjected to extension by a polymerase in a nucleic acid amplification reaction with the target nucleic acid, and

wherein a MET/FRET signal is generated from donor and acceptor on amplification of said target nucleic acid sequence when the MET/FRET moieties are separated by 4–20 or 25 nucleotides in the amplification product.

160. (New) The method of claim 159, wherein the primers are 10-40 nucleotides long and adapted for the amplification of a target segment of the size almost close to that of the primer dimer, wherein the length of the forward primer plus the length of the reverse primer is zero to twenty-five bases.

161. (New) A method of detection of target nucleic acid sequence by nucleic acid amplification reaction as claimed in claim 159, comprising the use of two oligonucleotides as a pair of primers for amplification of said target nucleic acid sequence, with one of them being

labeled with a donor/acceptor MET moiety, and a third oligonucleotide labeled with a complementary acceptor/donor MET moiety of a molecular energy transfer pair, wherein said third oligonucleotide is complementary to the sequence of the labeled primer and is extendable by the polymerase when provided unlinked, and is not extendable when provided linked to the 5' end of the said labelled primer through a non-oligonucleotide organic linker or linker and spacer, wherein both the labeled oligonucleotides are labeled suitably at least two bases away from their 3' ends.

162. (New) The method of claim 159, wherein a first oligonucleotide primer pair selected to amplify a first segment of the target nucleic acid is used, where one of the said oligonucleotide primer pair is provided unlabeled or labeled with a donor or an acceptor MET moiety a third oligonucleotide primer suitably labeled for MET with an acceptor or donor moiety respectively and designed to amplify a second segment of the first segment being provided such that , the donor moiety is optionally provided in quenched condition with a quencher following conventional methods.

163. (New) A method for nucleic acid detection or quantitation, wherein an acceptor or donor MET moiety on a labeled oligonucleotide primer is provided in quenched condition with a quencher following conventional methods such that the quencher is capable of absorbing the emission energy of the acceptor and quenching the same, and the donor or acceptor remains quenched only when there is no target amplification and the labeled oligonucleotide primers are the primers of claims 159-161.

164. (New) The method of claim 159, wherein both the acceptor and the donor-MET moieties are provided quenched with individual quenchers.

165. (New) The method of claim 159, wherein a first oligonucleotide primer pair is selected to amplify the target nucleic acid, a second oligonucleotide primer pair is selected to amplify a

second segment of the first segment in nested PCR, and said second oligonucleotide primer pair is any of the labeled oligonucleotide primer pairs of the claims 159-161.

166. (New) The method of nucleic acid detection by nucleic acid amplification of claim 159, providing a first oligonucleotide primer labeled with a first MET moiety at least 2 bases away from the 3' end, and a second oligonucleotide primer labeled with a second MET moiety at least 2 bases away from the 3' end, wherein either the first moiety is provided in quenched condition with a third MET moiety following conventional methods of quenching such that the quencher third moiety is capable of absorbing the emission energy of the first moiety, or a third MET moiety is provided that is quenched by said first moiety following conventional methods such that the first moiety is capable of absorbing the emission energy of the third MET moiety only when there is no target amplification;

wherein target amplification of the bases to which the first and the second MET moieties are attached are separated by a distance of 10 base pairs or more in the amplification product, wherein said first and second label moieties are the members of a first MET/FRET pair and said first and the third label moieties are the members of a second MET/FRET pair and said first and second MET/FRET pairs are the same or different.

167. (New) A method of high throughput detection or quantification of target nucleic acid comprising the steps of having a target nucleic acid that carries at its 3' or 5' end a non-target sequence 10–40 nucleotides long, a first amplification primer that is selected from the above non-target sequence, and a second amplification primer that is selected from the target sequence, wherein said first and second primers are suitably selected from the labeled primers of claims 159-161, 163-164 and 166.

168. (New) The method of claim 159, wherein multiple amplification primer pairs are provided for amplification of a multiplicity of target sequences.

169. (New) The method of claim 159, wherein the first or second oligonucleotide primer is attached or fixed covalently through the 5' end or an internal nucleotide to a solid support through a linker or linker and spacer, and other amplification primers and reagents are provided in an aqueous phase in contact with the said solid phase, the solid support to which the first oligonucleotide primer is attached is non-porous and transparent or translucent, glass, glass wafer, tubes or wells of a microtiter plate, or a plastic selected from the group consisting of polystyrene, polyethylene, and polypropylene.

170. (New) The method of claim 167, wherein multiples of said second oligonucleotide primer for amplification of multiple target sequences are attached or fixed covalently through the 5' end or an internal nucleotide to a solid support through a linker or linker and spacer, and a common or universal first oligonucleotide primer common for all target sequences and reagents are provided in an aqueous phase in contact with the said solid phase for the detection or quantitation of multiple target sequences in a sample;

wherein said solid support to which the second oligonucleotide primers are attached is non-porous and transparent or translucent, glass, glass wafer tubes or wells of a microtiter plate, or a plastic selected from the group consisting of: polystyrene, polyethylene, and polypropylene.

171. (New) The method of claim 159, wherein the label moiety is a MET/FRET moiety, and a MET/FRET moiety is a donor MET/FRET moiety or an acceptor MET/FRET moiety, where the acceptor is selected from radiative fluorophore that gives fluorescence, a non-radiative quencher; on illumination with its specific excitation radiation or light the donor moiety emits light or radiation, which is different from the light or radiation of illumination, and the acceptor moiety absorbs the light or radiation or energy emitted by the donor moiety and in turn emits radiation or light which is characteristic of the acceptor moiety and is different from that of the donor moiety as well as the light of illumination;

wherein a non-radiative quencher absorbs the energy or light emitted by the donor but does not emit any light or radiation;

wherein when the two donor and acceptor moieties come within a distance where the acceptor moiety can absorb the energy or emission of the donor moiety there is energy transfer from donor to acceptor, and the acceptor emits energy or light and the donor emission gets quenched, and when the acceptor or quencher is separated from the donor so that there can't be any energy transfer quenching of the donor gets removed and donor is able to emit energy or light;

wherein when more than two FRET moieties are used, different permitted combinations of suitable donor and acceptor moieties are used and a MET/FRET pair is a donor-acceptor pair.

172. (New) The method of claim 159, wherein the donor and acceptor moieties are selected from any of the known donor/acceptor FRET pairs,

wherein a FRET pair is a combination of a donor and an acceptor moiety such that the absorption spectra of the acceptor FRET moiety overlaps with at least 25% of the emission spectra of the donor FRET moiety, and the donor moiety is selected from the group consisting of fluorescein and fluorescein derivatives, carboxyfluorescein (FAM), coumarin, 5-(2' amino ethyl) amino naphthlene - 1 - sulfonic acid (EDANS), rhodamine, anthranilamide, , europium and terbium chelate derivatives, a combination of an organic moiety having a large extinction coefficient of absorpotion and a fluorophore;

wherein said acceptor moiety is selected from the group consisting of fluorescein, fluorescein derivatives, 2' 7' - dimethoxy 4'5' - dichloro-6-carboxyfluorescein (JOE), ethidium, sulforhodamine 101 (TEXAS REDTM), cosin, nitrotyrosine, malachite green, pyrene butyrate, 2-{{(E)-3-[1-(5-But-2-ynylcarbamoyl)pentyl]-3,3-dimethyl-5-sulfinoxy-1,3-dihydro-indol-(2E)-ylidene]-propenyl}-1-ethyl-3,3-dimethyl-5-sulfinooxy-3H-indolium (Cy3TM) dyes, 2-{{(1E,3E)-5-[1-(5-But-2-ynyl s carbamoyl)pentyl]-3,3-dimethyl-5-sulfinoxy-1,3-dihydro-indol-(2E)-ylidene]-penta-1,3-dienyl}-1-ethyl-3,3-dimethyl-5-sulfinooxy-3H-indolium (Cy5TM) dyes, 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL), DABCYL derivatives, rhodamine, rhodamine derivatives, 6-carboxy-X-rhodamine (ROX), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), Sulfonyl chloride derivative of sulforhodamine 101 (TEXAS

REDTM), gold nano particle, black hole quencher dyes (Azo linked aromatic species with conjugated pi-bonded system), and the quencher is selected from the group consisting of DABCYL and its derivatives, rhodamine and its derivatives, gold nano particles, black hole quencher dyes (Azo linked aromatic species with conjugated pi-bonded system).

173. (New) The method of claim 159, wherein the detection and/or quantitation of amplified target nucleic acid is accomplished by providing double-stranded DNA binding fluorescent dye selected from the group consisting of ethidium bromide, SYBR®Green (2-[2-((3-Dimethylaminopropyl-propyl)-amino)-1-phenyl-1H-quinolin-(4E)-ylidenemethyl]-3-methyl benzothiazol-3-ium); PICOGREEN® [2-[N-bis-(3-dimethylaminopropyl)-amino]-4-[2,3-dihydro-3-methyl(benzol-2-yl)-methylidene]-1-phenyl quinolinium; ACRIDINE ORANGE (N,N,N',N'-Tetramethyl-acridine- 3,6,-diamine); THIAZOLE ORANGE (1-Methyl-4-[(3-methyl-2(3H)- benzothiazolylidene)-methyl] quinolinium p-tosylate) YO-PRO® 1 (Quinolinium,4-O(((3-methyl-2-(3H)benzoxazolidene) methyl-1-O3-trimethylaminopropyl)-diiodide) and chromomycin A3 (3B-O-(4-O-acetyl-2,6-dideoxy-3-(C-methyl-alpha-L-arabino-hexopyranosyl)-7-methylolivomycin D) suitable to act as a donor or an acceptor.

174. (New) The method of claim 172, wherein fluorescein labeled primer and double-stranded DNA binding dye Ethidium bromide are used;

wherein fluorescein acts as a donor and ethidium acts as an acceptor for FRET to take place between the two.

175. (New) The method for the detection and/or quantification of an amplified target nucleic acid sequence as in claim 159, wherein one of the primers is labeled with a binding moiety selected from the group consisting of biotin, streptavidin, magnetic particle, microsphere, a hapten, an anchor oligonucleotide linked directly or linked through a linker to the said primer; and

wherein there is provided a capture moiety attached to a well of a microtiter plate or a tube or a glass wafer for capturing the respective binding moiety, wherein the capture moiety is selected from streptavidin, biotin, magnet, anti-hapten antibody, a capture oligonucleotide;

wherein the microsphere is captured by a capturing process like centrifugation;

wherein a suitable fluorescent intercalating dye or a suitable fluorescent dye labelled nucleotide capable of acting as donor or acceptor is provided, or a primer labeled with a binding moiety selected from biotin, streptavidin, hapten, microsphere at least two bases away from 3' end and another primer labeled with fluorescent dye or luminescent rare earth metal chelate, fluorescent or gold nano particle, streptavidin, biotin or hapten and suitable conjugate and substrates are provided.

176. (New) The method of claim 159, wherein said nucleic acid amplification reaction comprises any known nucleic acid amplification reactions including polymerase chain reaction comprising the steps of adding a polymerase or polymerases, reaction buffer, deoxynucleoside triphosphates in addition to the effective amounts of amplification primers and other oligonucleotides and reagents to the sample, carrying out an initial denaturation followed by repeated cycles of a denaturation step and a selective annealing step, or repeated cycles of a denaturation step, a selective annealing step and an extension step, and an optional final extension step, exciting the reaction mixture with a donor exciting radiation or light, measuring the emission of an acceptor FRET moiety, or that of the donor.

177. (New) The method of claim 159, wherein said oligonucleotide primers are linear oligonucleotide or duplex oligonucleotide in which a complementary oligonucleotide is joined to the 5' end of the priming oligonucleotide with a non-oligonucleotide organic linker or a linker and a spacer and are selected from the group comprising DNA, RNA or chimeric mixtures, derivatives or modified versions thereof adapted for hybridizing and priming nucleic acid amplification reaction, and are deoxy oligonucleotides, oligonucleotide or peptide or locked nucleic acid or modified oligonucleotides (contains modified base, sugar or backbone); the target

nucleic acid sequence is selected from genomic DNA, mRNA, RNAs, cDNA, amplification product, chemically or biochemically synthesized DNA or RNA.

178. (New) The method of claim 159, wherein the nucleic acid amplifications are a polymerase chain reaction (PCR), or a reverse transcription PCR (RT-PCR), or an allele specific PCR, or a methylation status PCR, or an in situ PCR, or a Triamplification, or an isothermal amplification reaction, including Nucleic acid sequence based amplification (NASBA), or Strand displacement amplification, or an immuno PCR.

179. (New) The method of claim 159, wherein the target nucleic acid sequence is one of:
an amplification product or the sequence of an infectious disease agent,
a genomic sequence of a human, animal, plant or any other living organism, a mutation in which is implicated to the presence of a disorder or disease,
a human, animal or plant genomic sequence, the presence or absence of which is implicated to a disorder or disease,
a human, animal or plant genomic sequence, the presence or absence of which is implicated to susceptibility to an infectious agent,
a human, animal, plant or any living organism genomic sequence the presence or absence of which is implicated to a genetic trait or genotyping of human, animal, plant, or the living organism,
a genomic sequence of an infectious agent, the presence or absence of which is implicated to strain typing, or
a sequence of a gene a mutation of which is related to a particular allele of the gene.

180. (New) The method of claim 159, wherein for the heterozygous mutation detection which comprises two amplification primer oligonucleotides, one labeled with a donor MET moiety near 3' end and the other being labeled with an acceptor MET moiety near 3' end, wherein a target amplification reaction and a thermal denaturation analysis of the amplification product or

products thus amplified is carried out and in the same method, the labeled oligonucleotide primers are also being provided in dual labeled quenched primer configuration.

181. (New) The method of claim 159, wherein the first and second oligonucleotides are selected from the group consisting of:

Seq Id 10: 5' – GGG GTA CTA CAG CGC CCT GA – 3'

Seq Id 19: 5' – GGG GTA CTA CAG CGC CCT GA – 3'

|
FAM

Seq Id 13: 5' – GTC CTG GAA GAT GGC CAT GG – 3'

Seq Id 20: 5' – GTC CTG GAA GAT GGC CAT GG – 3'

|
JOE

Seq Id 12: 5' – ATG GCC ATC GTC CTG GAA GAT GGC CAT GG – 3'

Seq Id 22: 5' – DABCYL-ATG GCC ATC GTC CTG GAA GAT GGC
CAT GG – 3'

|
JOE

Seq Id 23: 5' – DABCYL-ATG GCC ATC GTC CTG GAA GAT GGC
CAT GG – 3'

|
FAM

Seq Id 24: 5' – GCT CAT GGC GCC TGC CTG G – 3'

|
DABCYL

Seq Id 11: 5' – ATG GCC ATG TCC TGG AAG ATG GCC ATG G-3'

Seq Id -21: 5' – GGG GTA CTA CAG CGC CCT – 3' Seq Id -21

|
FAM

Seq Id 25: 5' – GTC CTG GAA GAT GGC CAT GG – 3'

|
Rhod

Seq Id 26: 5'- GTC CTG GAA GAT GGC CAT GG – 3'

|
JOE

Seq Id 29: 5' GGC AAT GAA AAG CCA CTT CT – 3' as a forward primer to
amplify a 50 base pair segment (base position 23, 565-23, 614) of
E.coli genome; and

Seq Id 30: 5' TTA ACC GGC GAT TGA GTA CC – 3' as a reverse primer to
amplify a 50 base pair segment (base position 23, 565-23, 614) of
E.coli genome.